Home
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Type 1 Issues Articles
Popular Type 1 Issues Articles
Highly Recommended Type 1 Issues Articles
Email to a Friend
Send a link to this page to your friends and colleagues.
Pfizer Halts Sales of Exubera In Wake of Lung Cancer Fears
In wake of news that its inhaled insulin product Exubera has been linked to lung cancer, Pfizer Inc. has announced that it will cease manufacturing the drug and update labels on the remaining product to carry a cancer warning.
The company revealed that in a study of 4,740 patients taking Exubera, six developed lung cancer (1 out of every 780). In comparison, one out of 4,292 patients in the study who were not taking Exubera developed lung cancer.
Pfizer introduced Exubera in 2006 as the first inhaled insulin product on the market. By 2007, however, the company announced that it would cease marketing the product because of low demand. An estimated 4,000 people with diabetes worldwide are taking the drug.
Before receiving FDA approval to market Exubera, the drug’s apparent effects on lung function had been noted in studies – a concern that delayed approval for several years.
Inhaled insulin has been a kind of Holy Grail for pharmaceutical manufacturers since it avoids the pain and inconvenience of needle injections. When Pfizer ceased marketing Exubera last year, Novo Nordisk and Eli Lilly soon dropped their inhaled insulin development programs.
Valencia, Calif.-based MannKind Corp. has said it will continue work on its Technosphere inhaled insulin product.
Addendum:
Oramed Begins Studies on Oral Insulin Capsule
Israeli company Oramed Pharmaceuticals, Inc., a developer of oral delivery systems, has commenced Phase 2A studies on its oral insulin capsule at the Hadassah Medical Center in Jerusalem. The trial will focus on assessing the safety and efficacy of the capsule on 10 type 2 diabetes patients. This study is a continuation of the recently successfully completed Phase 1 studies in Israel.
Categories: Diabetes, Diabetes, Insulin, Novo Nordisk, Type 1 Issues, Type 2 Issues
You May Also Be Interested In...
-
Diabetes Health
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
-
Topics
- Diabetic / Diabetes Health
- Type 1 / 1.5 Diabetes
- Type 2 Diabetes
- Blood Glucose / Sugar
- High/Low Blood Sugar / Fast Acting Glucose
- Insulin- Pumps, Pens & Syringes
- Continuous Glucose Monitors, CGM, Infusion Sets
- Type 2 Medications
- Hyperglycemia
- Hypoglycemia
Comments
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register...
Register your Diabetes Health Username here.
Have Your Say...